These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 12397699

  • 1. [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
    Kumagai H, Sakata K, Matsuura T, Imai M, Onami T, Iigaya K, Saruta T.
    Nihon Rinsho; 2002 Oct; 60(10):2005-13. PubMed ID: 12397699
    [Abstract] [Full Text] [Related]

  • 2. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 3. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 5. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 6. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
    Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.
    Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
    [Abstract] [Full Text] [Related]

  • 7. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 8. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F.
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [Abstract] [Full Text] [Related]

  • 9. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
    Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M.
    Nephrol Dial Transplant; 2004 Jul; 19(7):1716-23. PubMed ID: 15128880
    [Abstract] [Full Text] [Related]

  • 10. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, Gianni M, Guasti L, Venco A.
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [Abstract] [Full Text] [Related]

  • 11. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Feb; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 12. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
    Berger ED, Bader BD, Ebert C, Risler T, Erley CM.
    J Hypertens; 2002 Apr; 20(4):739-43. PubMed ID: 11910311
    [Abstract] [Full Text] [Related]

  • 13. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P, Fairley K, Packham D.
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [Abstract] [Full Text] [Related]

  • 14. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.
    Nephron Clin Pract; 2005 Apr; 99(1):c18-23. PubMed ID: 15637459
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 16. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 17. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic allograft injury.
    Shah PR, Kute VB, Saboo DS, Goplani KR, Gumber MR, Vanikar AV, Patel HV, Trivedi HL.
    Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1128-32. PubMed ID: 22089769
    [Abstract] [Full Text] [Related]

  • 20. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.